About Catalent, Inc. 
Catalent, Inc.
Pharmaceuticals: Major
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.
Company Coordinates 
Company Details
14 Schoolhouse Rd , SOMERSET NJ : 08873-1213
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 133 Schemes (49.83%)
Foreign Institutions
Held by 310 Foreign Institutions (34.01%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. John Chiminski
Chairman of the Board, Chief Executive Officer
Mr. Jack Stahl
Lead Independent Director
Mr. Madhavan Balachandran
Independent Director
Mr. J. Martin Carroll
Independent Director
Mr. Rolf Classon
Independent Director
Ms. Rosemary Crane
Independent Director
Revenue and Profits:
Net Sales:
1,023 Million
(Quarterly Results - Sep 2024)
Net Profit:
-129 Million
Pharmaceuticals: Major
USD 11,522 Million (Mid Cap)
NA (Loss Making)
NA
9,934.82%
1.30
-5.80%
3.25






